<DOC>
	<DOC>NCT01901900</DOC>
	<brief_summary>This extension study will provide continuing treatment with secukinumab for up to 3 years for subjects who completed the phase III core study, CAIN457F2302. Subjects will be offered maintenance treatment with secukinumab at the 150 mg given subcutaneously every 4 weeks. The study aims to obtain further long term efficacy, safety and tolerability information on secukinumab for patients with rheumatoid arthritis.</brief_summary>
	<brief_title>Safety and Efficacy of Extended Treatment With Secukinumab in Anti-TNF Inadequate Responders in RA.</brief_title>
	<detailed_description />
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis, Rheumatoid</mesh_term>
	<mesh_term>Antibodies, Monoclonal</mesh_term>
	<criteria>Subjects must give a written informed consent before any assessment is performed. Subjects must have completed the 104week treatment period in the core study Subjects who are deemed by the investigator to benefit from continued secukinumab therapy. Use of other investigational drugs except for secukinumab during the core study. Pregnant or nursing (lactating) women, where pregnancy is defined as the state of a female after conception and until the termination of gestation, confirmed by a positive hCG laboratory test. Women of childbearing potential, defined as all women physiologically capable of becoming pregnant, unless they are using effective methods of contraception during dosing of study treatment.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>moderate to severe RA</keyword>
	<keyword>anti-TNF inadequate responders</keyword>
</DOC>